Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + Cord Blood Transplant in Elderly AML
NCT03913312Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Primary endpoint: Disease Free Survival at 3 years. Status: unknown.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03913312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913312.